Healthcare - Biotechnology - NASDAQ - US
$ 7.445
-7.29 %
$ 631 M
Market Cap
-14.6
P/E
CASH FLOW STATEMENT
-27.8 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
29.7 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Anavex Life Sciences Corp.
| Net Income | -47.5 M |
| Depreciation & Amortization | -2.72 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 16.4 M |
| Change in Working Capital | 2.5 M |
| Others | 2.37 M |
| Free Cash Flow | -27.8 M |
Cash Flow
Millions
| Sep-2023 | Sep-2022 | Sep-2021 | Sep-2020 | Sep-2019 | Sep-2018 | Sep-2017 | Sep-2016 | Sep-2015 | Sep-2014 | Sep-2013 | Sep-2012 | Sep-2011 | Sep-2010 | Sep-2009 | Sep-2008 | Sep-2007 | Sep-2006 | Sep-2005 | Sep-2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||||||
| Net Income | (47.5) | (48.0) | (37.9) | (26.3) | (26.3) | (17.5) | (13.5) | (14.7) | (12.1) | (11.4) | (3.7) | (8.3) | (7.3) | (8.8) | (5.5) | (5.4) | (1.6) | 25.5 K | 91.6 K | 14.4 K |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.25 K | 995 | 768 | 576 | 1.86 K | 1.66 K | 910 | 410 | 220 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58.1 K | 0.5 | 5.6 | 0.5 | 3.9 | 8.4 | 0.5 | 0.8 | (1.7) | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 16.4 | 18.4 | 8.2 | 4.9 | 6.4 | 5.5 | 4.1 | 5.1 | 1.6 | 0.6 | 1.0 | 0.3 | 1.3 | 0.8 | 0.8 | 1.7 | 0 | 0 | 0 | 0 |
| Other Operating Activities | 0.8 | 13.3 | 11.8 | 6.6 | 35.4 K | 5.6 | 75.2 K | (0.1) | 4.5 | 2.8 | 1.0 | 0.1 | (7.3) | 3.0 | 0.2 | 2.4 | 0.8 | 2.38 K | 16 K | 0 |
| Change in Working Capital | 2.5 | 5.4 | (0.7) | 0.1 | 1.3 | (0.6) | 0.4 | 0.6 | 1.2 | (0.3) | 0.5 | 2.3 | 1.2 | 60.9 K | 0.9 | 0.5 | 0.5 | 9.27 K | 14.6 K | 2.5 K |
| Cash From Operations | (27.8) | (24.2) | (30.4) | (21.3) | (18.5) | (12.6) | (9.0) | (9.2) | (4.2) | (2.7) | (0.8) | (1.7) | (3.8) | (4.6) | (2.8) | (2.5) | (0.3) | 32.4 K | 61.1 K | 11.9 K |
| INVESTING CASH FLOW | ||||||||||||||||||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.02 K | 0 | 0 | 0 | 3.31 K | 1.24 K | 1.08 K | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.02 K | 0 | 0 | 0 | 3.31 K | 1.24 K | 1.08 K | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.0 | 0.2 | 0.6 | 0.8 | 1.4 | 1.2 | 1.4 | 0 | 20 K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.8 | 0.3 | 23.4 K | (0.4) | 50 K | (0.1) | 0 | 3.1 | 88.1 K | (0.8) | 0.9 | 8.15 K | 100 K | 0 | 0.3 | 0 | 0.3 | 23.7 K | 9.94 K | 0 |
| Cash From Financing Activities | 29.7 | 21.3 | 153.2 | 28.4 | 17.8 | 8.1 | 27.3 | 3.1 | 12.3 | 9.6 | 1.1 | 1.6 | 3.7 | 4.5 | 3.1 | 2.5 | 0.3 | 43.7 K | 33.9 K | 40 K |
| CHANGE IN CASH | ||||||||||||||||||||
| Net Change In Cash | 1.9 | (2.9) | 122.9 | 7.1 | (0.7) | (4.5) | 18.3 | (6.1) | 8.0 | 6.9 | 0.3 | (0.1) | (0.1) | 86.3 K | 0.3 | 6.33 K | 12.2 K | 11.3 K | 27.1 K | 28.1 K |
| FREE CASH FLOW | ||||||||||||||||||||
| Free Cash Flow | (27.8) | (24.2) | (30.4) | (21.3) | (18.5) | (12.6) | (9.0) | (9.2) | (4.2) | (2.7) | (0.8) | (1.7) | (3.8) | (4.6) | (2.8) | (2.5) | (0.3) | 32.4 K | 61.1 K | 11.9 K |